The Ministry of Health, Labor and Welfare (MHLW) appears to be ready to begin post-launch drug price adjustments based on cost-effectiveness assessments (CEAs) for the first time since the system was introduced in April 2019. As price tweaks will be…
HOME > BUSINESS
BUSINESS
- Meiji to Discontinue Sale of Kobayashi Kako Products after Biz Suspension
February 26, 2021
- Mylan EPD Offering EpiPen for Free to Prep for Possible Vaccine Reactions
February 26, 2021
- Daiichi Sankyo, France/Belgium Lymphoma Group to Collaborate on Valemetostat Trial
February 26, 2021
- MSD’s 9-Valent HPV Vaccine Now Available in Japan
February 25, 2021
- Ken Takeshita to Become Daiichi Sankyo’s Global R&D Head in April
February 25, 2021
- Takeda Launches Japan PI/II Trial of Novavax COVID-19 Vaccine
February 25, 2021
- Japan Pharma Market Shrinks 2.4% on COVID-19, Price Cuts: IQVIA
February 24, 2021
- Taiho’s HSP90 Inhibitor Extends PFS in GIST
February 24, 2021
- Lusefi’s OD Film Version Filed in Japan: Taisho
February 24, 2021
- Astellas’ Hot Flash Drug Hits Primary Goals in PIII Studies
February 22, 2021
- Astellas/Seagen Seek Padcev’s Full Approval, Label Expansion in US
February 22, 2021
- Chugai to Develop Atea’s COVID-19 Drug AT-527 in Japan
February 22, 2021
- Japan-Bound Flights for COVID-19 Vaccines Get Underway: Pfizer, DHL, ANA
February 22, 2021
- Mitsubishi Tanabe, Keio University Tie Up for Research of Neutralizing Antibodies for COVID-19
February 22, 2021
- Nipro to Boost Production of Low Dead Space Syringes
February 19, 2021
- Ono Sets Up Investigation Panel on Bribery Issue
February 19, 2021
- Kyowa Kirin’s Novel Antibody Hits Primary Goal in Global PII for Atopic Dermatitis
February 19, 2021
- Ono Files Opdivo for Adjuvant Therapy for Esophageal Cancer in Japan
February 19, 2021
- Chugai Re-Files Patent Suit over Edirol, Now Focuses on Crystalline Form
February 18, 2021
- Mitsubishi Tanabe Accelerating Drug Discovery via Open Innovation, Early-Stage Data Sharing
February 18, 2021
ページ
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
By managing personal bias during the interview process, hiring managers can significantly improve their hit rate placing winning candidates. The trouble is, it’s easier said than done. It’s only natural we tend to like people we can relate to, people…